Helbig W
Z Gesamte Inn Med. 1976 Apr 15;31(8):232-9.
The prognosis of lymphogranulomatosis has improved by the considerably improved diagnostics as well as the modern radiological and polychemo-therapeutical methods. Today the average survival time is between 4 and 5 years. But survival times up to 15 years and more are described. Apart from the early diagnosis, into which according to the opinion of many internal specialists the otorhinolaryngologists must be included more than it was hitherto the case, nowadays the modern radiotherapy with explorative laparotomy and splenectomy and the perhaps following combination chemotherapy might bring a further improvement. Growing age, histological types with a small number of lymphocytes, too late diagnosis and deficient control decrease, however, signigicantly the chances of surviving. Certainly, in future more modern methods of chemotherapy must be used. The same applies to the treatment of the developing immunoinsufficiency and the eventual further performance of the cytostatic treatment in the sense of a maintenance therapy. From the modern point of view the way taken might lead to still higher survival times. In as far immunotherapy will be of greater importance already in the next years is not yet to be decided at present.
随着诊断技术的显著改进以及现代放射学和多化疗方法的应用,淋巴肉芽肿的预后已有所改善。如今,平均生存时间在4至5年之间。但也有生存时间长达15年及以上的报道。除了早期诊断(许多内科专家认为耳鼻喉科医生在其中的参与度应比以往更高)之外,如今采用探索性剖腹术和脾切除术的现代放疗以及随后可能进行的联合化疗或许会带来进一步的改善。然而,年龄增长、淋巴细胞数量少的组织学类型、诊断过晚以及控制不足都会显著降低生存几率。当然,未来必须采用更现代的化疗方法。这同样适用于对免疫功能不全发展的治疗以及从维持治疗角度最终进一步进行的细胞抑制治疗。从现代观点来看,所采取的方法可能会带来更高的生存时间。至于免疫疗法在未来几年是否会变得更加重要,目前尚未确定。